Sensei Biotherapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.14 12:47
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -3.62, beating the estimate of USD -4.11.

EBIT: As of FY2025 Q3, the actual value is USD -5.146 M.

Segment Revenue

  • Sensei Biotherapeutics, Inc. did not report any revenue from product sales as it is still in the clinical development stage and does not expect to generate revenue from product sales for several years.

Operational Metrics

  • Net Loss: The company reported a net loss of $16.4 million for the nine months ended September 30, 2025, compared to a net loss of $22.4 million for the same period in 2024, showing a decrease in net loss by $6.0 million.
  • Operating Expenses: Total operating expenses were $17.3 million for the nine months ended September 30, 2025, compared to $24.3 million for the same period in 2024, reflecting a decrease of $7.0 million.
  • Research and Development Expenses: These expenses were $8.8 million for the nine months ended September 30, 2025, compared to $14.1 million for the same period in 2024, a decrease of $5.3 million.
  • General and Administrative Expenses: These expenses were $8.5 million for the nine months ended September 30, 2025, compared to $10.2 million for the same period in 2024, a decrease of $1.7 million.

Cash Flow

  • Net Cash Used in Operating Activities: The company used $16.6 million in net cash for operating activities during the nine months ended September 30, 2025, compared to $18.9 million for the same period in 2024.
  • Net Cash Provided by Investing Activities: The company generated $17.7 million from investing activities during the nine months ended September 30, 2025, compared to $25.6 million for the same period in 2024.
  • Net Cash Used in Financing Activities: The company used $0.5 million in net cash for financing activities during the nine months ended September 30, 2025, compared to $0.6 million for the same period in 2024.

Unique Metrics

  • Accumulated Deficit: As of September 30, 2025, the company had an accumulated deficit of $278.4 million.

Future Outlook and Strategy

  • Core Business Focus: The company has discontinued the development of its lead product candidate, solnerstotug, and is exploring strategic alternatives, including a sale of assets, licensing arrangements, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations.
  • Non-Core Business: As part of its strategic review process, the company plans to implement a reduction in force of approximately 65% of its workforce, incurring estimated cash expenditures of $1.6 million primarily for severance payments and other employee termination-related expenses.
  • Priority: The company is focused on maximizing shareholder value through strategic alternatives and managing its cash resources effectively to support ongoing operations during this period.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.